Standard Biotools Inc (LAB)vsNovartis AG ADR (NVS)
LAB
Standard Biotools Inc
$0.93
+4.69%
HEALTHCARE · Cap: $350.48M
NVS
Novartis AG ADR
$147.85
+3.44%
HEALTHCARE · Cap: $280.79B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 66317% more annual revenue ($56.67B vs $85.33M). NVS leads profitability with a 24.7% profit margin vs -87.8%. NVS earns a higher WallStSmart Score of 51/100 (C-).
LAB
Avoid31
out of 100
Grade: F
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LAB.
Margin of Safety
-52.2%
Fair Value
$109.78
Current Price
$147.85
$38.07 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Keeps 25 of every $100 in revenue as profit
Strong operational efficiency at 27.8%
Generating 2.9B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -13.1% — below average capital efficiency
Revenue declined 4.0%
2.2% revenue growth
Grey zone — moderate risk
Expensive relative to growth rate
Earnings declined 11.6%
Comparative Analysis Report
WallStSmart ResearchBull Case : LAB
The strongest argument for LAB centers on Price/Book.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 24.7% and operating margin at 27.8%.
Bear Case : LAB
The primary concerns for LAB are EPS Growth, Market Cap, Return on Equity.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, PEG Ratio.
Key Dynamics to Monitor
LAB profiles as a turnaround stock while NVS is a value play — different risk/reward profiles.
LAB carries more volatility with a beta of 1.42 — expect wider price swings.
NVS is growing revenue faster at 2.2% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 31/100), backed by strong 24.7% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Standard Biotools Inc
HEALTHCARE · MEDICAL DEVICES · USA
Standard Biotools Inc. (LAB) is a pioneering biotechnology company dedicated to enhancing genomic analysis and biological research through cutting-edge tools and technologies. The firm specializes in developing high-performance products that cater specifically to laboratories engaged in genomics and proteomics, thereby significantly improving research precision and operational efficiency. By employing proprietary platforms, Standard Biotools enables researchers to expedite discoveries and elevate the standard of their scientific endeavors. Positioned strategically within the rapidly evolving biotechnology sector, LAB is well-equipped to address the growing need for advanced analytical solutions that are essential to the life sciences industry.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?